Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
15 p, 3.4 MB Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS / Kuendgen, A. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tuechler, H. (Boltzmann Institute for Leukemia Research. Hanusch Hospital) ; Garcia-Manero, G. (Department of Leukemia. MD Anderson Cancer Center) ; Komrokji, R.S. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Sekeres, M.A. (Leukemia Program. Department of Hematology and Medical Oncology. Taussig Cancer Institute. Cleveland Clinic) ; Della Porta, M.G. (Cancer Center - IRCCS Humanitas Research Hospital & Humanitas University) ; Cazzola, M. (Department of Hematology Oncology. IRCCS Policlinico San Matteo Foundation) ; DeZern, A.E. (Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University) ; Roboz, G.J. (Weill Cornell Medicine and The New York Presbyterian Hospital) ; Steensma, D.P. (Dana-Farber Cancer Institute) ; Van de Loosdrecht, A.A. (Vrije Universiteit Amsterdam) ; Schlenk, R.F. (Department of Internal Medicine V. Heidelberg University Hospital) ; Grau, J. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Calvo, Xavier (Institut Hospital del Mar d'Investigacions Mèdiques) ; Blum, S. (Service of Hematology. University Hospital Lausanne) ; Pereira, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Valent, P. (Department of Internal Medicine I. Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology. Medical University of Vienna) ; Costa, D. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Giagounidis, A. (Department of Oncology. Hematology and Palliative Care. Marienhospital Duesseldorf) ; Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Döhner, H. (Department of Internal Medicine III. University Hospital Ulm) ; Platzbecker, U. (University Hospital Leipzig) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Lübbert, M. (Department of Hematology. Oncology and Stem Cell Transplantation. University Medical Center Freiburg. Faculty of Medicine) ; Oiartzabal, I. (Clinical Hematology Department. Hospital Universitario Araba) ; Díez-Campelo, M. (Clinical Hematology Department. Hospital Universitario de Salamanca (HUSA)) ; Cedena, M.T. (Hospital Universitario 12 de Octubre (Madrid)) ; Machherndl-Spandl, S. (1st. Internal Department - Hematology with stem cell transplants. Hemostaseology and Medical Oncology. Elisabethinen Hospital) ; López-Pavía, M. (Clinical Hematology Department. Hospital General Universitari de València) ; Baldus, C.D. (Department of Hematology and Oncology. University Hospital Schleswig-Holstein. Campus Kiel) ; Martinez-de-Sola, M. (Parc Taulí Hospital Universitari) ; Stauder, R. (Department of Internal Medicine V (Hematology and Oncology). Innsbruck Medical University) ; Merchan, B. (Hospital Universitari Vall d'Hebron) ; List, A. (Department of Malignant Hematology. H Lee Moffitt Cancer Center) ; Ganster, C. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Schroeder, T. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Voso, M.T. (Department of Biomedicine and Prevention. Tor Vergata University) ; Pfeilstöcker, M. (Hanusch Krankenhaus Wien) ; Sill, H. (Medizinische Universität Graz) ; Hildebrandt, B. (Institute of Human Genetics. University Duesseldorf) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Nomdedeu, B. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cobo, F. (Clinical Hematology Department. Hospital Quirón Teknon) ; Haas, R. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Germing, U. (Department of Hematology. Oncology. and Clinical Immunology. University Hospital Duesseldorf) ; Greenberg, P.L. (Stanford University Cancer Center) ; Haase, D. (Department of Hematology and Medical Oncology. University Medical Center Göttingen) ; Sanz, G. (Hospital Universitari i Politècnic La Fe de Valencia) ; Universitat Autònoma de Barcelona
In the current World Health Organization (WHO)-classification, therapy-related myelodysplastic syndromes (t-MDS) are categorized together with therapy-related acute myeloid leukemia (AML) and t-myelodysplastic/myeloproliferative neoplasms into one subgroup independent of morphologic or prognostic features. [...]
2020 - 10.1038/s41375-020-0917-7
Leukemia, 2020  
2.
8 p, 1.4 MB The expression level of BAALC -associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia / Díaz-Beyá, Marina (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brunet, Salut (Institut d'Investigació Biomèdica Sant Pau) ; Nomdedéu, J (Institut d'Investigació Biomèdica Sant Pau) ; Cordeiro, A (Universitat de Barcelona. Facultat de Medicina) ; Tormo, M (Hospital Clínic i Provincial de Barcelona) ; Escoda, L (Hospital Universitari Joan XXIII de Tarragona) ; Ribera, J M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Arnan, M (ICO, Hematology Department, Hospital Duran i Reynals, l'Hospitalet de Llobregat) ; Heras, Inmaculada (Hematology Department, Hospital Morales Meseguer) ; Gallardo Giralt, David (Hospital Universitari de Girona Doctor Josep Trueta) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Queipo de Llano, M P (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Salamero, O (Hospital Universitari Vall d'Hebron) ; Martí, J M (Hospital Universitari MútuaTerrassa) ; Sampol, A (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Pedro, Carme (Hospital del Mar (Barcelona, Catalunya)) ; Hoyos, M (Institut d'Investigació Biomèdica Sant Pau) ; Pratcorona, M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Castellano, J J (Universitat de Barcelona. Facultat de Medicina) ; Nomdedeu, Meritxell (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Risueño, R M (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Sierra, J (Institut d'Investigació Biomèdica Sant Pau) ; Monzó, M (Universitat de Barcelona. Facultat de Medicina) ; Navarro, A (Universitat de Barcelona. Facultat de Medicina) ; Esteve Reyner, Jordi (Hospital Clínic i Provincial de Barcelona) ; Universitat Autònoma de Barcelona
Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. [...]
2015 - 10.1038/bcj.2015.76
Blood Cancer Journal, Vol. 5 (october 2015) , p. e352  
3.
15 p, 1.7 MB The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature / Díaz-Beyá, Marina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Brunet Mauri, Maria Salut (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Nomdedéu Guinot, Josep Francesc (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Pratcorona, Marta (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cordeiro, Anna (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gallardo Giralt, David (Institut Català d'Oncologia) ; Escoda, Lourdes (Hospital Universitari Joan XXIII de Tarragona) ; Tormo, Mar (Hospital Clínic Universitari (València)) ; Heras, Inmaculada (Hospital General Universitario Morales Meseguer (Múrcia)) ; Ribera Santasusana, J. M. (José María) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Duarte, Rafael (Institut Català d'Oncologia) ; Llano Queipo, María Paz de (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Bargay, Joan (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ; Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ; Nomdedeu, Meritxell (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Risueño, Ruth M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Hoyos, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ; Sierra Gil, Jorge (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Monzo, Mariano (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Navarro, Alfons (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Esteve Reyner, Jordi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Cooperative AML group CETLAM ; Universitat Autònoma de Barcelona
Long non-coding RNAs (lncRNAs) are deregulated in several tumors, although their role in acute myeloid leukemia (AML) is mostly unknown. We have examined the expression of the lncRNA HOX antisense intergenic RNA myeloid 1 (HOTAIRM1) in 241 AML patients. [...]
2015 - 10.18632/oncotarget.5148
Oncotarget, Vol. 6 Núm. 31 (October 2015)  

Vegeu també: autors amb noms similars
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.